Hypertensive crisis is a condition characterized by rapid and inappropriate symptomatic elevation of blood pressure that is commonly seen in Emergency Department. Oral or Sublingual Captopril is commonly used in the emergency department. The unpleasant tast of the sublingual drugs causes uncomfortable condition to the patient. Studies showing on difference between oral and sublingual Captopril has been ignored sofar. Herein we compared the oral and sublingual Captopril efficiency in the hypertensive urgencies. However clinical use requires the daily dose of 37.5- 75 mg to be taken at three times. The reason being the drug is highly water soluble, unstable in alkaline intestinal PH and decrease in bioavailability in presence of food. Various attempts have been made to regulate the release and increase the bioavailability of the drug. The treatment course was 2 weeks. After that, we compared angina, blood pressure, ECG and adverse drug reactions of the two group.
Cite this article:
Chaudhari Urvashi Rajaram. Review of Captopril Drug Formulation, Mechanism of action, Dosage, Use and Adverse drug reactions. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(2):157-0. doi: 10.52711/0975-4377.2021.00028
Chaudhari Urvashi Rajaram. Review of Captopril Drug Formulation, Mechanism of action, Dosage, Use and Adverse drug reactions. Research Journal of Pharmaceutical Dosage Forms and Technology. 2021; 13(2):157-0. doi: 10.52711/0975-4377.2021.00028 Available on: https://rjpdft.com/AbstractView.aspx?PID=2021-13-2-13
1. Siyad. A.R, Hypertension- Journal for drug and medicines, H.J.D. Med: vol- 3; April- October 2011.
2. C.Nithya Shanthi, Rakesh Gupta, Arun Kumar Mahato, International Journal of drug Development and Research: vol- 2; April- June- 2010.
3. Bolourtchian N, Hadifi N, Foroutan S M, Faghi, BS. Formulation and Optimization of Captopril D- optimal design. Iran. J. Pharma Res 2008:7:256-67.
4. Al- Saidan SM, Krishnaiah YSR, Patrol SS, Satyanarayana V. Invitro and Invivo evaluation of Guar gum matrix table for oral controlled release of water-soluble Diltiazem Hydrochloride. AAPS. Pharmacological. Sci. Tech. 2005;6: E14-21.
5. Ojoe E, Miyauchi EM, Kaneko TM, Velasco MVR, Consiglieri Vo. Influence of cellulose polymers type on invitro controlled release tablets containing the ophylline. Brazil. J. Pharm. Sci. 2007; 43: 572-579.
6. Nokhodchi A, Zadeh DH, Zadeh FM, Zadeh NT. Effect of various surfactants and their concentration on controlled release of Captopril from polymer matrices. Acta.Pharm. 2008;58:151-162.
7. Guittard GV, Carpenter HA, Quan ES, Wong PS, Hamel LG. Dosage form for delivery drug in short time period. 1993; U.S. Patent 5178867:12 Jan.
8. Https://www.ncbi.n/m.nih.gov/books/NBK 535386/
9. Gan Z, Huang D, Jiang J, LiY, LiH, KeY. Captopril alleviates hypertension induced renal damage, inflammation, and NF-KB activation. Braz J Med Biol Res. 2018; Sep 03;51:e7338.
10. Lezama- Martinez D, Flores- Monroy J, Fonseca- Coronado S, Hernandez- Campos ME, Valencia- Hernandez I, Martinez- Aguilar L. Combined Antihypertensive Therapies that Increase Expression of Cardioprotective Biomarkers Associated with the Renin- Angiotensin and Kallikrein- kinin Systems.J Cardiovasc Pharmacological. 2018; Dec; 72:291-295.
11. Chen YJ, Li LJ, Tang WL, Song JY, Qiu R, Li Q, Xue H, Wright JM. First- line drug inhibiting the Renin-Angiotensin system versus other first- line antihypertensive drugs classes for hypertension. Cochrane Database syst Rev.2018; Nov 14;11:CD008170.
12. Herman LL, Padala SA, Annamaraju P, Bashir K. Statpearls (internet). Statpearls Publishing; Treasure Island (FL): Jun22, 2020. Angiotensin converting Enzyme Inhibitors (ACEI).
13. http://archinte.jamanetwork.com/on 05/20/2012.